# Unichem Laboratories share price today (Unichem Laboratories Ltd, NSE: UNICHEMLAB)

> Unichem Laboratories share price today: ₹505.45 at the NSE close on 4 November 2026, up 9.9% in a year. Unichem Laboratories (NSE: UNICHEMLAB) is worth ₹3,557 crore, trades at a P/E of 29.1 and has closed between ₹284.05 and ₹638.75 over the past 52 weeks. > Unichem Laboratories Ltd's earnings have grown faster than its share price. Earnings per share grew +83.9% in a year while the price moved +9.9%. UNICHEMLAB · Pharma - Others · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/unichem-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹505.45 (+9.9% in a year)
- P/E: 29.1× (higher than 57% of the last 11 years)
- Revenue (Jun 2026): ₹633 Cr (+20.1% on a year ago)
- Profit (Jun 2026): ₹41.0 Cr
- Operating margin: 11.0% (+6.7 points on a year ago)
- ROCE: 4%, FY26

The main question: profits are rising, but only −62% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Unichem Laboratories share price today? Unichem Laboratories Ltd's share price was ₹505.45 at the close on 4 November 2026. It has been rising for 16 weeks. That is 4.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹284 and ₹639, and at that close it sat 62% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +154% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Unichem Laboratories this quarter? 7 points on a year earlier. 1. Indian funds and insurers (DIIs) cut their stake for 8 quarters in a row From 11.7% to 9.4% of the company by the September 2026 quarter. 2. Revenue grew again in the June 2026 quarter Revenue was ₹633 crore, +20.1% on a year earlier (₹527 crore), after 2 quarters of decline. 3. Operating margin up 6.7 points on a year earlier 11% in the June 2026 quarter, from 4.3%. ## What are Unichem Laboratories' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Unichem Laboratories reported revenue of ₹633 crore, up 20.1% from ₹527 crore a year earlier, and a profit of ₹41.0 crore, against a loss of ₹10.0 crore a year earlier. ### Unichem Laboratories results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹633 crore | ₹527 crore | +20.1% |
| Profit | ₹41.0 crore | loss of ₹10.0 crore | n/a |
| Earnings per share | ₹5.89 | ₹−1.49 | n/a |
| Operating margin | 11.0% | 4.3% | +6.7 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Unichem Laboratories share price history? Unichem Laboratories closed at ₹505.45 on 4 November 2026, up 9.9% from ₹460.10 a year earlier (7 November 2025) and up 126.5% over five years. Its highest weekly close since February 2016 was ₹899.65 on 8 November 2024. ### Unichem Laboratories share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹483.75 | +4.5% |
| 1 month ago · 1 Oct 2026 | ₹535.05 | −5.5% |
| 6 months ago · 8 May 2026 | ₹385.80 | +31.0% |
| 1 year ago · 7 Nov 2025 | ₹460.10 | +9.9% |
| 3 years ago · 3 Nov 2023 | ₹400.80 | +26.1% |
| 5 years ago · 4 Nov 2021 | ₹223.20 | +126.5% |
| 10 years ago · 4 Nov 2016 | ₹272.65 | +85.4% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹198.85 | +154.2% |
| Highest weekly close since February 2016 · 8 Nov 2024 | ₹899.65 | −43.8% |
| Lowest weekly close since February 2016 · 20 Mar 2020 | ₹91.65 | +451.5% |
| 52-week high (weekly close) · 10 Jul 2026 | ₹638.75 | −20.9% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹284.05 | +77.9% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 26 February 2016 to 4 November 2026.)

## What is the latest news on Unichem Laboratories? 4 Nov 2026: Unichem Laboratories closed at ₹505.45, up 4.5% on the week and down 5.5% on the month. Results for April to June 2026: Revenue up 20.1% on a year earlier. ## What dividend does Unichem Laboratories pay? Unichem Laboratories paid no dividend in the 12 months to 5 November 2026. The last was a dividend of ₹4 a share, ex-date 1 August 2022. ### Unichem Laboratories dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 1 Aug 2022 | ₹4 | Dividend |
| 22 Jul 2021 | ₹4 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Unichem Laboratories Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 7 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is Unichem Laboratories on? Unichem Laboratories is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 3558.785943152455](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Unichem Laboratories profitable? Unichem Laboratories Ltd earned ₹41.0 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹253 Cr. Over 10 years profit has grown 8.9% a year on average. That is 6.5% of the quarter's revenue. The same quarter a year earlier lost ₹10.0 Cr. 4 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹253 Cr (+83.3% on the year before). On average over the last four quarters, profit changed +42.7% and revenue +7.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Unichem Laboratories make, and is it growing? Unichem Laboratories Ltd reported ₹633 Cr of revenue in the Jun 2026 quarter, +20.1% on the same quarter a year earlier. Over 10 years it has grown 5.1% a year on average. The last full year, FY26, came in at ₹2,202 Cr. The last four reported quarters add to ₹2,308 Cr. FY26 revenue was ₹2,202 Cr, +4.3% on the year before. Recent pace: the last four quarters grew +7.5% on average, against 5.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.1%, against +13.3% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Unichem Laboratories keep? Unichem Laboratories Ltd's operating margin was 11.0% in the Jun 2026 quarter, 6.7 percentage points higher than the same quarter a year ago. Across 13 years it has been between −16.0% and 16.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +6.8 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Unichem Laboratories' profit turning into cash? Over the last 3 years Unichem Laboratories Ltd's operations used more cash than they brought in, so cash conversion was −62%, a gap worth watching. In FY26 it brought in ₹4.0 Cr of operating cash against ₹253 Cr of profit. After ₹107 Cr of spending on assets, free cash was −₹103 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −62% of profit came in as cash: the cash cycle got 32 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Unichem Laboratories' cash go? Unichem Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 358 days in FY26, down from 390 days in FY21. It spent ₹282 Cr on assets over the last 3 years. Customers take 137 days to pay, and stock sits for 349 days on average. At FY26 sales of ₹2,202 Cr, each day of that cycle ties up about ₹6.0 Cr, so roughly ₹2,160 Cr is tied up in the business at any time. FY26: customers took 137 days to pay and stock sat for 349 days, about 11.5 months of sales sitting as stock, for a full cycle of 358 days, shorter than FY21's 390. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 349 days. Customers pay about 137 days after that. Suppliers are paid at 128 days. Together that makes the 358-day cycle. Spending on assets: ₹282 Cr over the last 3 years, against ₹373 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹100 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Unichem Laboratories' P/E ratio, and how does it compare with its own history? Unichem Laboratories Ltd's P/E is 29.1×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 26.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +83.9% while the price moved +9.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +17.8% a year; about +43.0% a year came from earnings growth and about −25.2 percentage points from the multiple (the market paying less); over 10 years the price moved +6.4% a year; about +3.8% a year came from earnings growth and about +2.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 338% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Unichem Laboratories business getting better or worse? Unichem Laboratories Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Unichem Laboratories earn on its capital? Unichem Laboratories Ltd earned a ROCE of 4% in FY26. That is up from a low of −5% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 11.5% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.5% net margin × 0.59× asset turnover × 1.36× leverage (assets divided by equity) ≈ 9.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 338% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Unichem Laboratories have too much debt? Unichem Laboratories Ltd had ₹500 Cr of borrowings against ₹2,717 Cr of equity in FY26, so its debt is 0.18× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹119 Cr to ₹500 Cr. Over the last 3 of those years it spent ₹282 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 338% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Unichem Laboratories shareholding pattern? Domestic institutions cut their stake in Unichem Laboratories Ltd by 2.3 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.4% of the company. Foreign institutions moved +1.8 points over the same period, to 2.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −2.3 points over 8 quarters, to 9.4%; Foreign institutions: +1.8 points over 8 quarters, to 2.7%; Promoters: +0.0 points over 8 quarters, to 70.2%. Why the owners changed: foreign institutions moved +1.8 points and domestic institutions −2.3 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Unichem Laboratories from balance-sheet trouble? For Unichem Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Unichem Laboratories rank in its industry? 38.3 out of 100, rank 6 of 10 in Pharma - Others, with 64% of the evidence available. Unichem Laboratories Ltd scores 38.3 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 13.4 + 6.6 + 10 + 8.3 = 38.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Unichem Laboratories compared with? Unichem Laboratories ranks 6 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 38.3 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 71.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.8/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.8 + 15.1 + 17.8 = 71.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.3/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16.3 + 15 + 4.3 = 61.4 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Unichem Laboratories Ltd this page UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 17.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 17.4 + 11.1 = 59.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.5/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.5 + 14.3 = 56.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Unichem Laboratories in size? Unichem Laboratories is the 2nd largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sun Pharma Advanced Research Company. Just below it: Shukra Pharmaceuticals, Panacea Biotec, Syncom Formulations (India), JOJO and TTK Healthcare. ### Pharma - Others companies close in size

1. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) ₹5,727 crore
2. Unichem Laboratories Ltd ₹3,406 crore
3. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) ₹3,313 crore
4. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
5. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
6. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
7. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Aimtron Electronics Ltd](https://www.sectoralpha.in/stocks/aimtron-electronics-ltd) ₹3,420 crore · EMS
2. [RattanIndia Power Ltd](https://www.sectoralpha.in/stocks/rattanindia-power-ltd) ₹3,415 crore · Power - Generation/Distribution
3. Unichem Laboratories Ltd ₹3,406 crore
4. [Raymond Realty Ltd](https://www.sectoralpha.in/stocks/raymond-realty-ltd) ₹3,394 crore · Realty - Regional
5. [Kaveri Seed Company Ltd](https://www.sectoralpha.in/stocks/kaveri-seed-company-ltd) ₹3,390 crore · Miscellaneous

## What else do people ask about Unichem Laboratories? ### What is Unichem Laboratories's share price today? Unichem Laboratories Ltd's share price is ₹505.45, +9.9% over the past year. The whole company is worth ₹3,557 Cr on the market. In the last 52 weeks it traded between ₹284 to ₹639; today it is 62% of the way up from the low, 4.2% above its 200-day average (as of 4 November 2026). ### What were Unichem Laboratories's latest quarterly results? Unichem Laboratories Ltd reported revenue of ₹633 Cr and net profit of ₹41.0 Cr for the Jun 2026 quarter. Earnings per share were ₹5.89. The operating margin was 11.0%, 6.7 percentage points higher than a year earlier (as of 4 November 2026). ### What is Unichem Laboratories's market cap? Unichem Laboratories Ltd's market capitalisation is ₹3,557 Cr at a share price of ₹505.45. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Unichem Laboratories performing? Unichem Laboratories Ltd's share price has been rising for 16 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Unichem Laboratories's share price go up? This page does not forecast Unichem Laboratories Ltd's share price. What it shows instead: the share price is ₹505.45, and it has been rising for 16 weeks. Its P/E of 29.1× is higher than 57% of its own last 11 years (as of 4 November 2026). ### Who owns Unichem Laboratories? Promoters own 70.2% of Unichem Laboratories Ltd, foreign institutions 2.7%, domestic institutions 9.4% and the public 17.7% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 2.3 percentage points over 8 quarters (as of 4 November 2026). ### Where is Unichem Laboratories in its business cycle? Unichem Laboratories Ltd's FY26 operating margin was 9.0%, against a 13-year range of −16.0% to 16.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Unichem Laboratories story? The main question: profits are rising, but only −62% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Unichem Laboratories a stock worth studying right now? What the numbers show: Unichem Laboratories Ltd's earnings have grown faster than its share price. Earnings per share grew +83.9% in a year while the price moved +9.9%. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.